Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mauro Paoluzzi

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Brachytherapy|December 6, 2011
Is prostate-specific antigen percentage decrease predictive of clinical outcome after permanent iodine-125 interstitial brachytherapy for prostate cancer?Mauro Paoluzzi, Marcello Mignogna, Elena Lorenzini, et al.
Brachytherapy|June 24, 2017
Prostate-specific antigen percentage: An early predictive tool after iodine-125 interstitial brachytherapy for prostate cancerMauro Paoluzzi, Andrea Losa, Valentina Cerboneschi, et al.
The British Journal of Radiology|July 8, 2016
Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutionsGiovanni Fellin, Maria A Mirri, Luigi Santoro, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Brachytherapy|December 6, 2011
Is prostate-specific antigen percentage decrease predictive of clinical outcome after permanent iodine-125 interstitial brachytherapy for prostate cancer?Mauro Paoluzzi, Marcello Mignogna, Elena Lorenzini, et al.
Brachytherapy|June 24, 2017
Prostate-specific antigen percentage: An early predictive tool after iodine-125 interstitial brachytherapy for prostate cancerMauro Paoluzzi, Andrea Losa, Valentina Cerboneschi, et al.
The British Journal of Radiology|July 8, 2016
Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutionsGiovanni Fellin, Maria A Mirri, Luigi Santoro, et al.
Pageof 1